Skip to main content
Clinical Trials/NCT01138878
NCT01138878CompletedNot Applicable

HIV Testing in Non-traditional Settings Study

Chelsea and Westminster NHS Foundation Trust4 sites in 1 country6,350 target enrollmentStarted: July 2009Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
6,350
Locations
4
Primary Endpoint
(1) Feasibility of delivering opt-out HIV testing in ED/ACU/OPD/Primary Care setting

Study Overview

Brief Summary

Surveillance data suggests that approximately one third of the 82 000 HIV infected adults in the UK remain undiagnosed - that is, they are living with the infection but do not know this. The majority of HIV testing in the UK to date has taken place in sexual health clinics and in antenatal care. Published National guidelines advocate routine HIV testing of 16-65 year olds in more general healthcare settings in parts of the country with relatively high rates of HIV (more than 2 per thousand individuals diagnosed locally). The HINTS Study investigates the utility, feasibility and acceptability, to patients and staff, of offering routine HIV testing in four general medical settings, all set in areas of high HIV prevalence. The settings comprise: Primary Care, Outpatients, an Acute Care Unit and an Emergency Department.

Study Design

Study Type
Observational
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
16 Years to 65 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • known HIV positive
  • unable to provide adequate contact details
  • unable to provide consent (to HIV test and/or participation in questionnaire/focus group/semi-structured interview studies)

Outcomes

Primary Outcomes

(1) Feasibility of delivering opt-out HIV testing in ED/ACU/OPD/Primary Care setting

Time Frame: At end of twelve week testing period at each site

Secondary Outcomes

  • (2) Estimate of prevalence of undiagnosed HIV with risk factor/demographic assessment(At end of twelve week testing period)

Investigators

Sponsor
Chelsea and Westminster NHS Foundation Trust
Sponsor Class
Other

Study Sites (4)

Loading locations...

Similar Trials

Completed
Not Applicable
Evaluation of apolipoprotein A2 isoforms and discovery of disease biomarkers by multi-omics study in population of medical checkupspancreatic cancer
JPRN-UMIN000025857Division of gastroenterology, Department of internal medicine, Kobe university Graduate school of medicine5,120
Terminated
Not Applicable
SARS-CoV-2 OTC At Home TestCOVID-19 Pandemic
NCT055539643EO Health64
Active, not recruiting
Phase 1
Estudio fase III internacional randomizado, doble ciego, con grupos de tratamiento paralelos para evaluar la seguridad y eficacia de ocrelizumab comparado con placebo en pacientes con artritis reumatoide activa en tratamiento con metotrexato. - NAArtritis Reumatoide
EUCTR2006-005147-28-ESF. Hoffmann-La Roche Ltd1,000
Completed
Phase 3
Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal InfectioComplicated Intra-abdominal Infection
JPRN-jRCT2061210026Kawai Norisuke60
Active, not recruiting
Phase 1
Estudio de fase III, randomizado, abierto, para comparar la farmacocinética, eficacia y seguridad de trastuzumab por vía subcutánea (SC) con trastuzumab por vía intravenosa (IV) administrado a mujeres con cáncer de mama precoz (CMP) HER2 positivo.Cáncer de mama localmente avanzado, inflamatorio o en estadio inicial HER2 positivoMedDRA version: 9.1Level: LLTClassification code 10006194Term: Breast cancer NOS stage IMedDRA version: 9.1Level: LLTClassification code 10006195Term: Breast cancer NOS stage IIMedDRA version: 9.1Level: LLTClassification code 10006196Term: Breast cancer NOS stage IIIMedDRA version: 9.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancer
EUCTR2008-007326-19-ESF. Hoffmann-La Roche Ltd552